Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieternella Lugtenburg; Irit Avivi; Henriette Berenschot; Osman Ilhan; Jean Pierre Marolleau; Arnon Nagler; Antonio Rueda; Monica Tani; Mehmet Turgut; Stuart Osborne; Rodney Smith; Michael Pfreundschuh; Adrian Tempescul

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieternella Lugtenburg Irit Avivi ¹ Henriette Berenschot Osman Ilhan Jean Pierre Marolleau ² Arnon Nagler ³ Antonio Rueda Monica Tani Mehmet Turgut Stuart Osborne Rodney Smith Michael Pfreundschuh ⁴ Adrian Tempescul ⁵

1 Tel Aviv Sourasky Medical Center [Te Aviv]

2 CHU - Centre Hospitalier Universitaire d'Amiens

3 Service d'Hématologie [AP-HP Hôpital Saint-Antoine]

4 Saarland University Medical School

5 CIC Brest

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Life Sciences [q-bio] / Human health and pathology

Life Sciences [q-bio] / Human health and pathology / Hematology

Life Sciences [q-bio] / Cancer

Complete list of metadatas

https://hal.univ-brest.fr/hal-02049783
Contributor : Ghislaine Calvez <>
Submitted on : Tuesday, February 26, 2019 - 4:10:29 PM
Last modification on : Wednesday, February 27, 2019 - 1:09:41 AM

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Identifiers

Collections

Citation

Export

Metrics

31

Contact

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Identifiers

Collections

Citation

Export

Share

Metrics

31

Contact